Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract

Patent metadata

Field	Value
Publication number	US-10639319-B2
Application number	US-201214238822-A
Country	US
Kind code	B2
Filing date	Aug 13, 2012
Priority date	Aug 29, 2011
Publication date	May 5, 2020
Grant date	May 5, 2020

Abstract

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, children, and adults for preventing injury and/or improving the healing of the gastrointestinal tract. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.

First claim

What is claimed is:

1. A method of stimulating the healing response of an individual's gastrointestinal tract, the method comprising:
administering a nutritional composition comprising a human milk oligosaccharide selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, 2′-fucosyllactose, 3-fucosyllactose, lacto-N-neotetraose, disialyllacto-N-tetraose, and combinations thereof to an individual having an injured gastrointestinal tract, wherein the individual's gastrointestinal tract is injured as a result of at least one of radiation therapy, chemotherapy, enteric infection, inflammatory bowel disease, colitis, and bowel obstruction;
wherein the nutritional composition comprises 0.01 mg to less than 2 mg of the human milk oligosaccharide per mL of the composition, and
wherein administration of the nutritional composition stimulates at least one mucin-associated protein selected from TFF3, MUC2, and RELMβ.

2. The method of claim 1 wherein the nutritional composition comprises 2′-Fucosyllactose.

3. The method of claim 1 wherein the nutritional composition further comprises at least one probiotic.

4. The method of claim 1 , wherein the nutritional composition is selected from the group consisting of a human milk fortifier, an infant formula, a pediatric formula, a follow-on formula, and an adult nutritional composition.

5. The method of claim 4 , wherein the nutritional composition is an infant formula.

6. The method of claim 4 , wherein the nutritional composition comprises 2′-Fucosyllactose and at least one probiotic.

7. A method of reducing the incidence of intestinal mucosa injury, the method comprising:
administering a nutritional composition comprising a human milk oligosaccharide selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, 2′-fucosyllactose, 3-fucosyllactose, lacto-N-neotetraose, disialyllacto-N-tetraose, and combinations thereof to an individual susceptible to an intestinal mucosa injury;
wherein the nutritional composition comprises 0.01 mg to less than 2 mg of the human milk oligosaccharide per mL of the composition, and
wherein administration of the nutritional composition stimulates at least one mucin-associated protein selected from TFF3, MUC2, and RELMβ.

8. The method of claim 7 wherein the nutritional composition comprises 2′-Fucosyllactose.

9. The method of claim 7 wherein the nutritional composition further comprises at least one probiotic.

10. The method of claim 7 wherein the nutritional composition is selected from the group consisting of a human milk fortifier, an infant formula, a pediatric formula, a follow on formula, and an adult nutritional composition.

11. A method of stimulating the expression of one or more mucin-associated proteins in an individual's gastrointestinal tract, the method comprising:
administering a nutritional composition comprising a human milk oligosaccharide selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, 2′-fucosyllactose, 3-fucosyllactose, lacto-N-neotetraose, disialyllacto-N-tetraose, and combinations thereof to an individual in need thereof
wherein the nutritional composition comprises 0.01 mg to less than 2 mg of the human milk oligosaccharide per mL of the composition, and
wherein administration of the nutritional composition stimulates at least one mucin-associated protein selected from TFF3, MUC2, and RELMβ.

12. The method of claim 11 wherein the nutritional composition comprises 2′-Fucosyllactose.

13. The method of claim 11 wherein the nutritional composition further comprises at least one probiotic.

14. A method of reducing the incidence of inflammation in an individual's gastrointestinal tract, the method comprising:
administering a nutritional composition comprising a human milk oligosaccharide selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, 2′-fucosyllactose, 3-fucosyllactose, lacto-N-neotetraose, disialyllacto-N-tetraose, and combinations thereof to an individual susceptible to inflammation of the gastrointestinal tract;
wherein the nutritional composition comprises 0.01 mg to less than 2 mg of the human milk oligosaccharide per mL of the composition, and
wherein administration of the nutritional composition stimulates at least one mucin-associated protein selected from TFF3, MUC2, and RELMβ.

Assignees

• Davis Steven R
• Chow Jomay
• Abbott Lab

Inventors

• Davis Steven R
• Chow Jomay

Classifications

• A23L33/40

  Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title

• A61K35/747

  Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title

• A61K31/702 Primary

  Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title

• A61K35/741

  Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title